North America Transdermal Drug Delivery System Market Forecast to 2030
North America Transdermal Drug Delivery System Market Forecast to 2030 – Regional Analysis – by Type (Transdermal Patches, Transdermal Gel, Transdermal Sprays, and Others), Application (Cardiovascular Diseases, Central Nervous System Disorders, Pain Management, Hormonal Applications, and Other Applications), and Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
$2,840 – $4,440
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
The North America transdermal drug delivery system market is expected to grow from US$ 14,977.62 million in 2022 to US$ 20,958.37 million by 2030. It is estimated to register a CAGR of 4.3% from 2022 to 2030.
Increasing Prevalence of Chronic Diseases Drives North America Transdermal Drug Delivery System Market
Cardiovascular diseases (CVDs) such as angina, atherosclerosis, pectoris, and acute myocardial infarction are among the common causes of mortality in the world. According to the WHO, CVDs are the major cause of ~17.9 million deaths worldwide every year. Many medicines are commercially available for the treatment of CVDs but conventional capsules and tablets are unable to effectively control the ailment. This underlines the need for novel drug delivery systems providing prolonged drug bioavailability and targeted drug delivery to the affected areas of the cardiovascular system. Transdermal drug delivery systems offer many advantages over regular orally administered drugs to treat cardiovascular diseases. Transdermal patches, encompassing drug particles, are applied on the skin surface. A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently shows promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. They work by relaxing the blood vessels and reducing the stress on the heart, thereby lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.
According to the Alzheimer’s association report, in 2019, Alzheimer disease was ranked sixth and in 2020 and 2021 it was ranked seventh among the leading causes of death in in the US. According to the 2023 stats by the National Institute of Health, ~6.7 million Americans (i.e., 1 in 9 people or 10.8% of the population), aged 65 and older, have Alzheimer’s dementia. The percentage of people with Alzheimer’s dementia increases with age. 5% of people aged 65-74, 13.1% aged 75-84, and 33.3% aged 85 and above have Alzheimer’s dementia. According to the “Global Prevalence of Young-Onset Dementia” report published in 2021, the prevalence of younger-onset dementia in the US is estimated at 110 of every 100,000 people aged 30-64 years, or ~200,000 Americans in total. Rivastigmine patch is used to treat dementia (memory loss) associated with mild, moderate, or severe Alzheimer’s disease or mild-to-moderate dementia associated with Parkinson’s disease. Rivastigmine and donepezil are cholinesterase inhibitors exhibiting a dose-response relationship, with higher doses of the drugs demonstrating greater efficacy. It is a small, lipophilic, and hydrophilic molecule that is chemically well-suited for transdermal delivery.
Diabetes is a life-threatening chronic disease having no specialized cure. Both types of diabetes can lead to various problems in different body parts and increase the overall risk of premature death. According to the International Diabetes Federation (IDF) Diabetes Atlas 10th edition reports, in 2021, globally 537 million adults (20-79 years) were diabetic, and the number is likely to reach 643 million by 2030 and 783 million by 2045. Exogenous insulin is usually administered subcutaneously for diabetes management. However, the recent attention toward a smart patch that delivers insulin when needed, simplifying insulin intake and activating targeted action.
Thus, the increasing incidences of chronic diseases such as cardiovascular diseases, Alzheimer’s disease, and diabetes bolster the growth of the transdermal drug delivery system market.
North America Transdermal Drug Delivery System Market Overview
The North American transdermal drug delivery system market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America transdermal drug delivery system market. The growing innovations in the transdermal drug delivery systems and increasing central nervous system disorders are among the few factors projected to accelerate the growth of the North America transdermal drug delivery system market during the forecast period. Moreover, increasing R&D activities and the introduction of novel products are propelling the market for transdermal drug delivery systems. According to the American Heart Association (AHA), cardiovascular disease (CVD) remains the leading cause of death in the US. According to the CDC, in 2021, CVD accounted for ~695,000 deaths and ~1 in 5 deaths in the US. The rising prevalence of cardiovascular disease, diabetes, chronic pain conditions, and other chronic diseases drives the demand for effective and convenient treatment options. Medical patches offer a noninvasive and patient-friendly approach to deliver medication and manage symptoms associated with these chronic conditions. Ongoing advancements in TDDS, such as wearable sensors and flexible electronics, contribute to the growth of the transdermal drug delivery system market. These advancements allow for more accurate dosing, enhanced patient monitoring, and improved patient compliance. According to a report titled “Recent advances in transdermal drug delivery systems,” published by Biomaterials Research in 2021, microneedles attract significant attention among TDDS modalities, which overcome the limitations of the existing simple application type and patch-type needles by combining the advantages of microneedles to obtain higher treatment efficiency and effects. Advances in these TDDS can provide the driving force for controlling the prevalence of cardiovascular and central nervous system diseases, diabetes, neuromuscular diseases, and infectious and localized infectious diseases.
The growing trend of personalized medicines, where treatments are tailored to individual patients, has boosted the development of medical patches that offer controlled and targeted drug delivery. This customization allows for better patient outcomes and improved therapeutic efficacy. For instance, in 2020, Reddy’s Laboratories launched an Authorized Generic Version of NitroDur (nitroglycerin) Transdermal Infusion System in the US market. With the growing emphasis on home healthcare and remote patient monitoring, medical patches offer a convenient solution for delivering medications and monitoring vital signs outside traditional healthcare settings. The US transdermal drug delivery system market is influenced by factors such as the increasing prevalence of chronic diseases, rising technological advancements, and growing focus on personalized medicines.
North America Transdermal Drug Delivery System Market Revenue and Forecast to 2030 (US$ Million)
North America Transdermal Drug Delivery System Market Segmentation
The North America transdermal drug delivery system market is segmented into type, application, distribution channel, and country.
Based on type, the North America transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the North America transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.
In terms of application, the North America transdermal drug delivery system market is segmented into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the North America transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.
Based on distribution channel, the North America transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the North America transdermal drug delivery system market in 2022.
Based on country, the North America transdermal drug delivery system market is segmented into the US, Canada, and Mexico. The US dominated the North America transdermal drug delivery system market in 2022.
Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, Purdue Pharma LP, UCB SA, and Viatris Inc are some of the leading companies operating in the North America transdermal drug delivery system market.
Increasing Prevalence of Chronic Diseases Drives North America Transdermal Drug Delivery System Market
Cardiovascular diseases (CVDs) such as angina, atherosclerosis, pectoris, and acute myocardial infarction are among the common causes of mortality in the world. According to the WHO, CVDs are the major cause of ~17.9 million deaths worldwide every year. Many medicines are commercially available for the treatment of CVDs but conventional capsules and tablets are unable to effectively control the ailment. This underlines the need for novel drug delivery systems providing prolonged drug bioavailability and targeted drug delivery to the affected areas of the cardiovascular system. Transdermal drug delivery systems offer many advantages over regular orally administered drugs to treat cardiovascular diseases. Transdermal patches, encompassing drug particles, are applied on the skin surface. A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently shows promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. They work by relaxing the blood vessels and reducing the stress on the heart, thereby lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.
According to the Alzheimer’s association report, in 2019, Alzheimer disease was ranked sixth and in 2020 and 2021 it was ranked seventh among the leading causes of death in in the US. According to the 2023 stats by the National Institute of Health, ~6.7 million Americans (i.e., 1 in 9 people or 10.8% of the population), aged 65 and older, have Alzheimer’s dementia. The percentage of people with Alzheimer’s dementia increases with age. 5% of people aged 65-74, 13.1% aged 75-84, and 33.3% aged 85 and above have Alzheimer’s dementia. According to the “Global Prevalence of Young-Onset Dementia” report published in 2021, the prevalence of younger-onset dementia in the US is estimated at 110 of every 100,000 people aged 30-64 years, or ~200,000 Americans in total. Rivastigmine patch is used to treat dementia (memory loss) associated with mild, moderate, or severe Alzheimer’s disease or mild-to-moderate dementia associated with Parkinson’s disease. Rivastigmine and donepezil are cholinesterase inhibitors exhibiting a dose-response relationship, with higher doses of the drugs demonstrating greater efficacy. It is a small, lipophilic, and hydrophilic molecule that is chemically well-suited for transdermal delivery.
Diabetes is a life-threatening chronic disease having no specialized cure. Both types of diabetes can lead to various problems in different body parts and increase the overall risk of premature death. According to the International Diabetes Federation (IDF) Diabetes Atlas 10th edition reports, in 2021, globally 537 million adults (20-79 years) were diabetic, and the number is likely to reach 643 million by 2030 and 783 million by 2045. Exogenous insulin is usually administered subcutaneously for diabetes management. However, the recent attention toward a smart patch that delivers insulin when needed, simplifying insulin intake and activating targeted action.
Thus, the increasing incidences of chronic diseases such as cardiovascular diseases, Alzheimer’s disease, and diabetes bolster the growth of the transdermal drug delivery system market.
North America Transdermal Drug Delivery System Market Overview
The North American transdermal drug delivery system market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America transdermal drug delivery system market. The growing innovations in the transdermal drug delivery systems and increasing central nervous system disorders are among the few factors projected to accelerate the growth of the North America transdermal drug delivery system market during the forecast period. Moreover, increasing R&D activities and the introduction of novel products are propelling the market for transdermal drug delivery systems. According to the American Heart Association (AHA), cardiovascular disease (CVD) remains the leading cause of death in the US. According to the CDC, in 2021, CVD accounted for ~695,000 deaths and ~1 in 5 deaths in the US. The rising prevalence of cardiovascular disease, diabetes, chronic pain conditions, and other chronic diseases drives the demand for effective and convenient treatment options. Medical patches offer a noninvasive and patient-friendly approach to deliver medication and manage symptoms associated with these chronic conditions. Ongoing advancements in TDDS, such as wearable sensors and flexible electronics, contribute to the growth of the transdermal drug delivery system market. These advancements allow for more accurate dosing, enhanced patient monitoring, and improved patient compliance. According to a report titled “Recent advances in transdermal drug delivery systems,” published by Biomaterials Research in 2021, microneedles attract significant attention among TDDS modalities, which overcome the limitations of the existing simple application type and patch-type needles by combining the advantages of microneedles to obtain higher treatment efficiency and effects. Advances in these TDDS can provide the driving force for controlling the prevalence of cardiovascular and central nervous system diseases, diabetes, neuromuscular diseases, and infectious and localized infectious diseases.
The growing trend of personalized medicines, where treatments are tailored to individual patients, has boosted the development of medical patches that offer controlled and targeted drug delivery. This customization allows for better patient outcomes and improved therapeutic efficacy. For instance, in 2020, Reddy’s Laboratories launched an Authorized Generic Version of NitroDur (nitroglycerin) Transdermal Infusion System in the US market. With the growing emphasis on home healthcare and remote patient monitoring, medical patches offer a convenient solution for delivering medications and monitoring vital signs outside traditional healthcare settings. The US transdermal drug delivery system market is influenced by factors such as the increasing prevalence of chronic diseases, rising technological advancements, and growing focus on personalized medicines.
North America Transdermal Drug Delivery System Market Revenue and Forecast to 2030 (US$ Million)
North America Transdermal Drug Delivery System Market Segmentation
The North America transdermal drug delivery system market is segmented into type, application, distribution channel, and country.
Based on type, the North America transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the North America transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.
In terms of application, the North America transdermal drug delivery system market is segmented into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the North America transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.
Based on distribution channel, the North America transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the North America transdermal drug delivery system market in 2022.
Based on country, the North America transdermal drug delivery system market is segmented into the US, Canada, and Mexico. The US dominated the North America transdermal drug delivery system market in 2022.
Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, Purdue Pharma LP, UCB SA, and Viatris Inc are some of the leading companies operating in the North America transdermal drug delivery system market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
At 4.3% CAGR, North America Transdermal Drug Delivery System Market is Speculated to be Worth US$ 20,958.37 Million by 2030, says the Research Team
According to the Research Team research, the North America transdermal drug delivery system market was valued at US$ 14,977.62 million in 2022 and is expected to reach US$ 20,958.37 million by 2030, registering a CAGR of 4.3% from 2022 to 2030. Increasing prevalence of chronic diseases and strategic initiatives by manufacturers are among the critical factors attributed to the North America transdermal drug delivery system market expansion.
Manufacturers in the transdermal drug delivery market are ramping up their focus on the adoption of various strategies such as type innovations and launches, product approvals, R&D investments (for advancements), and mergers and acquisitions to maintain a competitive edge in the market.
In February 2023, Revive Therapeutics Ltd. established a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-methylenedioxymethamphetamine (MDMA) using PharmaTher’s novel microneedle patch (MN-patch) delivery technology. The MDMA MN-patch enables flexible drug load capacity and combinations, controlled released delivery, and the ability to present desired pharmacokinetic and safety profiles, overcoming the potential obstacles of oral dosing.
In September 2022, Biomind and the Queen’s University of Belfast received a controlled substances license to begin manufacturing a novel transdermal drug delivery system. This disruptive drug delivery approach can go beyond a full psychedelic experience. Biomind is likely to provide a next-generation treatment for inflammation, pain, and neurodegenerative disorders through this comfortable drug delivery solution, strongly emphasizing improving patient therapeutic outcomes.
In September 2022, Corium, Inc launched ADLARITY (donepezil transdermal system), now available for prescription in the US for treating patients with mild, moderate, or severe dementia of Alzheimer’s type.
In 2019, the US FDA approved Noven’s schizophrenia treatment administered through a once-daily transdermal delivery system. In 2019, Nemaura Pharma Limited, a UK-based biopharmaceutical company specializing in transdermal and injectable drug delivery systems, announced a strategic collaboration with Sparsha USA. Based in California, Sparsha specializes in the development and commercial manufacturing of transdermal patches and oral thin films.
Such strategic initiatives are likely to result in future trends in the transdermal drug delivery system market in the coming years.
On the contrary, adverse effects and recall of transdermal drug delivery systems hamper the growth of North America transdermal drug delivery system market.
Based on type, the North America transdermal drug delivery system market is categorized into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held 39.5% share of North America transdermal drug delivery system market in 2022, amassing US$ 5,912.94 million. It is projected to garner US$ 8,440.95 million by 2030 to expand at 4.5% CAGR during 2022-2030. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.
In terms of application, the North America transdermal drug delivery system market is segmented into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held 40.4% share of North America transdermal drug delivery system market in 2022, amassing US$ 6,045.66 million. It is projected to garner US$ 8,456.34 million by 2030 to expand at 4.3% CAGR during 2022-2030. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.
By distribution channel, the North America transdermal drug delivery system market is categorized into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held 43.3% share of North America transdermal drug delivery system market in 2022, amassing US$ 6,487.03 million. It is projected to garner US$ 9,068.88 million by 2030 to expand at 4.3% CAGR during 2022-2030.
Based on country, the North America transdermal drug delivery system market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 82.0% share of North America transdermal drug delivery system market in 2022. It was assessed at US$ 12,283.38 million in 2022 and is likely to hit US$ 17,287.32 million by 2030, exhibiting a CAGR of 4.4% during 2022-2030.
Key players operating in the North America transdermal drug delivery system market are Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, Purdue Pharma LP, UCB SA, and Viatris Inc, among others.
In August 2023, Novartis acquired Chinook Therapeutics Inc. Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront. The deal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin A receptor antagonist, and zigakibart, an anti-APRIL monoclonal antibody.
In June 2022, “Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech company. Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Boehringer Ingelheim is dedicated to a two-pronged research strategy to fight cancers: through cancer cell-directed and immune cell-targeting compounds. The ongoing research partnership between Boehringer Ingelheim and Trutino is part of an overarching effort to mobilize a patient’s immune system to fight cancer.”
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Transdermal Drug Delivery System Market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America Transdermal Drug Delivery System Market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America Transdermal Drug Delivery System Market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Transdermal Drug Delivery System Market – Key Industry Dynamics
4.1 Market Drivers
4.1.1 Increasing Prevalence of Chronic Diseases
4.1.2 Growing Demand for Noninvasive Drug Delivery Devices
4.1.3 High Demand for Self-Administration of Drugs
4.2 Market Restraints
4.2.1 Adverse Effects and Recall of Transdermal Drug Delivery Systems
4.3 Market Opportunities
4.3.1 Advancements in Smart Patches and 3D-Printed Patches
4.4 Future Trends
4.4.1 Strategic Initiatives by Manufacturers
4.5 Impact Analysis
5. Transdermal Drug Delivery System Market – North America Market Analysis
5.1 North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2022 – 2030
6. North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Transdermal Patches
6.3.1 Overview
6.3.2 Transdermal Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Drug-in-Adhesive Patches
6.3.2.1.1 Overview
6.3.2.1.2 Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.2 Matrix Patches
6.3.2.2.1 Overview
6.3.2.2.2 Matrix Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.3 Reservoir Membrane Patches
6.3.2.3.1 Overview
6.3.2.3.2 Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.4 Vapor Patches
6.3.2.4.1 Overview
6.3.2.4.2 Vapor Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Transdermal Gels
6.4.1 Overview
6.4.2 Transdermal Gels: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Transdermal Sprays
6.5.1 Overview
6.5.2 Transdermal Sprays: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Others
6.6.1 Overview
6.6.2 Others: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cardiovascular Diseases
7.3.1 Overview
7.3.2 Cardiovascular Diseases: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Central Nervous System Disorders
7.4.1 Overview
7.4.2 Central Nervous System Disorders: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Pain Management
7.5.1 Overview
7.5.2 Pain Management: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.5.2.1 Opioid
7.5.2.1.1 Overview
7.5.2.1.2 Opioid: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.5.2.2 Non-Opioid
7.5.2.2.1 Overview
7.5.2.2.2 Non-Opioid: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Hormonal Applications
7.6.1 Overview
7.6.2 Hormonal Applications: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.6.2.1 Transdermal Estrogen & Progesterone Therapy
7.6.2.1.1 Overview
7.6.2.1.2 Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.6.2.2 Testosterone Replacement
7.6.2.2.1 Overview
7.6.2.2.2 Testosterone Replacement: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Other Application
7.7.1 Overview
7.7.2 Other Application: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – Country Analysis
9.1 North America Transdermal Drug Delivery System Market
9.1.1 North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
9.1.1.1 US: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Overview
9.1.1.1.2 US: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.3 US: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
9.1.1.1.3.1 US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
9.1.1.1.4 US: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
9.1.1.1.4.1 US: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
9.1.1.1.4.2 US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
9.1.1.1.5 US: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.2 Canada: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 Canada: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.3 Canada: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
9.1.1.2.3.1 Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
9.1.1.2.4 Canada: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
9.1.1.2.4.1 Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
9.1.1.2.4.2 Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
9.1.1.2.5 Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.3 Mexico: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 Mexico: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.3 Mexico: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
9.1.1.3.3.1 Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
9.1.1.3.4 Mexico: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
9.1.1.3.4.1 Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
9.1.1.3.4.2 Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
9.1.1.3.5 Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Transdermal Drug Delivery System Market Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Transdermal Drug Delivery System Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Johnson & Johnson
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Viatris Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Boehringer Ingelheim International GmbH
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Luye Pharma Group Ltd
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Lavipharm SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Purdue Pharma LP
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 UCB SA
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Transdermal Drug Delivery System Market – Key Industry Dynamics
4.1 Market Drivers
4.1.1 Increasing Prevalence of Chronic Diseases
4.1.2 Growing Demand for Noninvasive Drug Delivery Devices
4.1.3 High Demand for Self-Administration of Drugs
4.2 Market Restraints
4.2.1 Adverse Effects and Recall of Transdermal Drug Delivery Systems
4.3 Market Opportunities
4.3.1 Advancements in Smart Patches and 3D-Printed Patches
4.4 Future Trends
4.4.1 Strategic Initiatives by Manufacturers
4.5 Impact Analysis
5. Transdermal Drug Delivery System Market – North America Market Analysis
5.1 North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2022 – 2030
6. North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Transdermal Patches
6.3.1 Overview
6.3.2 Transdermal Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Drug-in-Adhesive Patches
6.3.2.1.1 Overview
6.3.2.1.2 Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.2 Matrix Patches
6.3.2.2.1 Overview
6.3.2.2.2 Matrix Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.3 Reservoir Membrane Patches
6.3.2.3.1 Overview
6.3.2.3.2 Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.4 Vapor Patches
6.3.2.4.1 Overview
6.3.2.4.2 Vapor Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Transdermal Gels
6.4.1 Overview
6.4.2 Transdermal Gels: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Transdermal Sprays
6.5.1 Overview
6.5.2 Transdermal Sprays: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Others
6.6.1 Overview
6.6.2 Others: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cardiovascular Diseases
7.3.1 Overview
7.3.2 Cardiovascular Diseases: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Central Nervous System Disorders
7.4.1 Overview
7.4.2 Central Nervous System Disorders: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Pain Management
7.5.1 Overview
7.5.2 Pain Management: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.5.2.1 Opioid
7.5.2.1.1 Overview
7.5.2.1.2 Opioid: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.5.2.2 Non-Opioid
7.5.2.2.1 Overview
7.5.2.2.2 Non-Opioid: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Hormonal Applications
7.6.1 Overview
7.6.2 Hormonal Applications: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.6.2.1 Transdermal Estrogen & Progesterone Therapy
7.6.2.1.1 Overview
7.6.2.1.2 Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.6.2.2 Testosterone Replacement
7.6.2.2.1 Overview
7.6.2.2.2 Testosterone Replacement: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Other Application
7.7.1 Overview
7.7.2 Other Application: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 – Country Analysis
9.1 North America Transdermal Drug Delivery System Market
9.1.1 North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
9.1.1.1 US: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Overview
9.1.1.1.2 US: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.3 US: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
9.1.1.1.3.1 US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
9.1.1.1.4 US: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
9.1.1.1.4.1 US: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
9.1.1.1.4.2 US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
9.1.1.1.5 US: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.2 Canada: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 Canada: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.3 Canada: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
9.1.1.2.3.1 Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
9.1.1.2.4 Canada: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
9.1.1.2.4.1 Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
9.1.1.2.4.2 Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
9.1.1.2.5 Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.3 Mexico: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 Mexico: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.3 Mexico: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
9.1.1.3.3.1 Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
9.1.1.3.4 Mexico: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
9.1.1.3.4.1 Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
9.1.1.3.4.2 Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
9.1.1.3.5 Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Transdermal Drug Delivery System Market Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Transdermal Drug Delivery System Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Johnson & Johnson
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 GSK Plc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Viatris Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Boehringer Ingelheim International GmbH
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Luye Pharma Group Ltd
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Lavipharm SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Purdue Pharma LP
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 UCB SA
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Transdermal Drug Delivery System Market Segmentation
Table 2. US: North America Transdermal Drug Delivery System Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 3. US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type – Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America Transdermal Drug Delivery System Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. US: North America Transdermal Drug Delivery System Market, For Pain Management by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application – Revenue and Forecast to 2030 (US$ Million)
Table 7. US: North America Transdermal Drug Delivery System Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada: North America Transdermal Drug Delivery System Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type – Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: North America Transdermal Drug Delivery System Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application – Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico: North America Transdermal Drug Delivery System Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico: North America Transdermal Drug Delivery System Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application – Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application – Revenue and Forecast to 2030 (US$ Million)
Table 19. Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 20. Recent Inorganic Growth Strategies in the Transdermal Drug Delivery System Market
Table 21. Recent Organic Growth Strategies in the Transdermal Drug Delivery System Market
Table 22. Glossary of Terms, North America Transdermal Drug Delivery System Market
Table 2. US: North America Transdermal Drug Delivery System Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 3. US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type – Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America Transdermal Drug Delivery System Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. US: North America Transdermal Drug Delivery System Market, For Pain Management by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application – Revenue and Forecast to 2030 (US$ Million)
Table 7. US: North America Transdermal Drug Delivery System Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada: North America Transdermal Drug Delivery System Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type – Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: North America Transdermal Drug Delivery System Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application – Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico: North America Transdermal Drug Delivery System Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico: North America Transdermal Drug Delivery System Market, by Application – Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application – Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application – Revenue and Forecast to 2030 (US$ Million)
Table 19. Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 20. Recent Inorganic Growth Strategies in the Transdermal Drug Delivery System Market
Table 21. Recent Organic Growth Strategies in the Transdermal Drug Delivery System Market
Table 22. Glossary of Terms, North America Transdermal Drug Delivery System Market
LIST OF FIGURES
Figure 1. North America Transdermal Drug Delivery System Market Segmentation, By Country
Figure 2. North America Transdermal Drug Delivery System Market: Key Industry Dynamics
Figure 3. North America Transdermal Drug Delivery System Market: Impact Analysis of Drivers and Restraints
Figure 4. North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2020 – 2030
Figure 5. North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
Figure 6. Transdermal Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Matrix Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Vapor Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Transdermal Gels: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Transdermal Sprays: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
Figure 15. Cardiovascular Diseases: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Central Nervous System Disorders: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Pain Management: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Opioid: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Non-Opioid: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Hormonal Applications: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Testosterone Replacement: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Other Application: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 25. Hospital Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Retail Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Online Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Others: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. North America Transdermal Drug Delivery System Market, by Key Country – Revenue (2022) (US$ Million)
Figure 30. North America: North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
Figure 31. US: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Canada: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. Mexico: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Growth Strategies in the Transdermal Drug Delivery System Market
Figure 2. North America Transdermal Drug Delivery System Market: Key Industry Dynamics
Figure 3. North America Transdermal Drug Delivery System Market: Impact Analysis of Drivers and Restraints
Figure 4. North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2020 – 2030
Figure 5. North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
Figure 6. Transdermal Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Matrix Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Vapor Patches: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Transdermal Gels: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Transdermal Sprays: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
Figure 15. Cardiovascular Diseases: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Central Nervous System Disorders: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Pain Management: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Opioid: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Non-Opioid: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Hormonal Applications: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Testosterone Replacement: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Other Application: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 25. Hospital Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Retail Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Online Pharmacies: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Others: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. North America Transdermal Drug Delivery System Market, by Key Country – Revenue (2022) (US$ Million)
Figure 30. North America: North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
Figure 31. US: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Canada: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 33. Mexico: North America Transdermal Drug Delivery System Market – Revenue and Forecast to 2030 (US$ Million)
Figure 34. Growth Strategies in the Transdermal Drug Delivery System Market
1. Boehringer Ingelheim International GmbH
2. GSK Plc
3. Hisamitsu Pharmaceutical Co Inc
4. Johnson & Johnson
5. Lavipharm SA
6. Luye Pharma Group Ltd
7. Novartis AG
8. Purdue Pharma LP
9. UCB SA
10. Viatris Inc
Be the first to review “North America Transdermal Drug Delivery System Market Forecast to 2030”
You must be logged in to post a review.
Reviews
There are no reviews yet.